Since traditional ERα antagonists (tamoxifen) act as GPR30 agonists increasing tumor invasiveness, in the future, co-inhibiting both the ERα and GPR30 receptors may provide a rational therapeutic strategy for the management of estrogen-dependent breast cancers [6, 16]. This evidence concerns the gene GPER1 and breast cancer.